EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05075577 |
|
Recruitment Status :
Recruiting
First Posted : October 13, 2021
Last Update Posted : May 13, 2024
|
Sponsor:
ESSA Pharmaceuticals
Information provided by (Responsible Party):
ESSA Pharmaceuticals
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a Phase 1/2 study of EPI-7386 orally administered in combination with enzalutamide in subjects with mCRPC.
Phase 1 of the study will be a single-arm dose escalation study of EPI-7386 in combination with a fixed dose of enzalutamide. This portion of the study will primarily evaluate the safety and tolerability of the drug combination and establish the RP2CDs for EPI-7386 and enzalutamide when dosed in combination. In addition, blood sampling will be conducted for PK evaluation to assess the potential DDI between the two drugs.
Once the RP2CD for each drug has been established, Phase 2 of the study will commence. Phase 2 is a two-arm, randomized (2:1), open-label study. Approximately 120 subjects will be randomized 2:1 to:
- Group 1: EPI-7386 at the RP2CD + enzalutamide(depending on the results of the Phase 1) (n=80)
- Group 2: Enzalutamide single agent (n=40) The planned dose of enzalutamide and EPI-7386 for the combination arm will be those determined in the Phase 1 of this study based on safety and exposure data. Subjects may remain on study treatment as long as they are tolerating treatment without disease progression based on RECIST v1.1 and/or PCWG3.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Prostate Cancer | Drug: Enzalutamide Drug: EPI-7386 with Enzalutamide | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 150 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer |
| Actual Study Start Date : | December 21, 2021 |
| Estimated Primary Completion Date : | August 2025 |
| Estimated Study Completion Date : | January 2026 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Prostate cancer
MedlinePlus related topics:
Prostate Cancer
Drug Information
available for:
Enzalutamide
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Phase 1 Cohort 1
600 mg QD EPI-7386 in combination of Enzalutamide120 mg
|
Drug: EPI-7386 with Enzalutamide
Daily oral dose of EPI-7386 in combination of enzalutamide |
|
Experimental: Phase 1 Cohort 2
800 mg QD EPI-7386 in combination of Enzalutamide120 mg
|
Drug: EPI-7386 with Enzalutamide
Daily oral dose of EPI-7386 in combination of enzalutamide |
|
Experimental: Phase 1 Cohort 3
600 mg BID EPI-7386 in combination of Enzalutamide120 mg
|
Drug: EPI-7386 with Enzalutamide
Daily oral dose of EPI-7386 in combination of enzalutamide |
|
Experimental: Phase 1 Cohort 4
RP2D mg EPI-7386 in combination of Enzalutamide160 mg
|
Drug: EPI-7386 with Enzalutamide
Daily oral dose of EPI-7386 in combination of enzalutamide |
|
Experimental: Phase 2 Enzalutamide + EPI-7386 (Randomized 2:1)
RP2D mg EPI-7386 in combination of Enzalutamide RP2D mg
|
Drug: EPI-7386 with Enzalutamide
Daily oral dose of EPI-7386 in combination of enzalutamide |
|
Active Comparator: Phase 2 Enzalutamide single agent
Enzalutamide 160 mg
|
Drug: Enzalutamide
Daily oral dose of enzalutamide |
Primary Outcome Measures :
- Phase 1: Incidence of Dose Limiting Toxicities [ Time Frame: Baseline to End of Cycle 1 (each cycle is 28 days) ]Characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for AEs [NCI CTCAE version 5.0]), timing in relation to study treatment administration, seriousness, and relationship to study treatment.
- Phase 1: Incidence of treatment emergent adverse events [ Time Frame: Baseline to 30 days after last dose of study drug ]Characterized by type, frequency, severity, timing, seriousness, and relationship to study treatment.
- Phase 1: Incidence of laboratory abnormalities as a measure of safety and tolerability of EPI-7386 [ Time Frame: Baseline to 30 days after last dose of study drug ]Characterized by type, frequency, severity, timing, seriousness, and relationship to study treatment.
- Phase 1: Changes in ECOG performance status [ Time Frame: Baseline to 30 days after last dose of study drug ]
- Phase 2: Proportion of subjects with a prostate-specific antigen decline of >50% (PSA50) at Week 12 [ Time Frame: Baseline to Week 12 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Gender Based Eligibility: | Yes |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Males ≥18 years.
- Histologically, pathologically, or cytologically confirmed prostate adenocarcinoma.
- Evidence of castration-resistant prostate cancer (CRPC).
- Presence of metastatic disease at study entry documented by 1 or more bone lesions on bone scan or by soft tissue disease observed by CT/MRI.
- Naïve to second generation anti-androgens.
- Evidence of progressive disease defined as 1 or more Prostate Cancer Working Group 3 (PCWG3) criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Ongoing ADT with luteinizing hormone-releasing hormone (LHRH) agonist/antagonist therapy or history of bilateral orchiectomy, with castrate level testosterone.
- Serum testosterone ≤1.73 nmol/L (50 ng/dL).
- Subjects receiving bisphosphonates or other approved bone-targeting therapy (e.g., denosumab) must be on a stable dose for at least 28 days prior to the start of study treatment.
- Demonstrate adequate organ function.
Exclusion Criteria:
- Biologic anti-cancer therapy within 28 days prior to the start of study treatment.
- Use of hormonal agents with anti-tumor activity against prostate cancer within 28 days prior to the start of study treatment.
- Use of herbal products or alternative therapies that may decrease PSA levels or that may have hormonal anti-prostate cancer activity within 28 days prior to the start of study treatment or plans to initiate during the study.
- Intervention with any chemotherapy, investigational agents, or other anti-cancer drugs within 28 days of the first dose of study treatment.
- Use of radium-223 dichloride or other radioligand/radiopharmaceutical within 28 days prior to the start of study treatment.
- Received limited-field palliative bone radiotherapy >5 fractions and/or any radiotherapy within 2 weeks prior to the start of study treatment.
- Received a blood transfusion within 28 days of hematologic screening labs.
- Known intra-cerebral disease or brain metastasis unless adequately treated and stable for the last 28 days before signing of informed consent.
- Spinal cord compression.
- Diagnosis of another clinically significant malignancy within the previous 3 years other than curatively treated non-melanomatous skin cancer or superficial urothelial carcinoma and other in situ or non-invasive malignancies.
- Gastrointestinal issues affecting absorption.
- Significant cardiovascular disease.
- Known history of seizure or conditions that may pre-dispose them to seizure, including brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain metastases, and brain arteriovenous malformation.
- Concurrent disease or any clinically significant abnormality.
- Known or suspected hypersensitivity to any components of the formulation used for EPI-7386 or enzalutamide.
- Use of strong inhibitors of CYP2C8.
- Use of strong inducers of CYP3A.
- Use of narrow therapeutic index sensitive CYP2C8 or sensitive substrates for CYP3A and CYP2B6.
- Use of granulocyte colony stimulating factor within 7 days prior to screening laboratories.
- Not a candidate for enzalutamide treatment.
- Patients with rare hereditary problems of fructose intolerance.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05075577
Contacts
| Contact: Karen Villaluna | 650-449-8400 | kvillaluna@essapharma.com |
Locations
Show 24 study locations
Sponsors and Collaborators
ESSA Pharmaceuticals
| Responsible Party: | ESSA Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT05075577 |
| Other Study ID Numbers: |
EPI-7386-CS-010 |
| First Posted: | October 13, 2021 Key Record Dates |
| Last Update Posted: | May 13, 2024 |
| Last Verified: | May 2024 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms |
Genital Diseases, Male Genital Diseases Urogenital Diseases Prostatic Diseases Male Urogenital Diseases |